2018 Half Year Investor Presentation
Filed with ASX · · 27 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
● The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- 2018 Half Year Media Release
- 2017 CEOs Speech
- Mayne Pharma launches clozapine tablets in the US
- Mayne Pharma adds two products to its Australian portfolio
- FDA approval and first generic launch of Acticlate tablets
Later from Mayne Pharma
- First generic launch of Ritalin LA 10mg capsules in the US
- Mayne Pharma launches doxycycline IR capsules in the US
- Mayne Pharmas generic NuvaRing accepted for filing by FDA
- Mayne Pharma launches Amiodarone 200mg tablets in the US
- Mayne Pharma opens new US manufacturing facility
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma